Mainstay Capital Management’s AbbVie ABBV Stock Holding History

Mainstay Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$327K	Buy	1,299 +15	+1%	+$3.23K	0.02%	117
2026 Q1	$279K	Buy	1,284 +25	+2%	+$5.55K	0.02%	125
2025 Q4	$288K	Buy	1,259 +5	+0.4%	+$1.14K	0.02%	107
2025 Q3	$290K	Sell	1,254 -1,468	-54%	-$299K	0.03%	99
2025 Q2	$505K	Buy	2,722 +1,361	+100%	+$253K	0.02%	94
2025 Q1	$285K	Buy	1,361 +10	+0.7%	+$1.94K	0.04%	84
2024 Q4	$240K	Hold	1,351	–	–	0.04%	94
2024 Q3	$267K	Sell	1,351 -5	-0.4%	-$933	0.04%	99
2024 Q2	$233K	Buy	1,356 +5	+0.4%	+$828	0.04%	107
2024 Q1	$246K	Hold	1,351	–	–	0.05%	103
2023 Q4	$209K	Sell	1,351 -2,114	-61%	-$308K	0.04%	106
2023 Q3	$516K	Buy	+3,465	New	+$509K	0.11%	61
2018 Q4	–	Sell	-241	Closed	-$23K	–	89
2018 Q3	$23K	Buy	241 +1	+0.4%	+$95	0.01%	279
2018 Q2	$22K	Buy	240 +40	+20%	+$3.91K	0.02%	264
2018 Q1	$19K	Sell	200 -2,410	-92%	-$265K	0.01%	212
2017 Q4	$252K	Buy	+2,610	New	+$246K	0.21%	87

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mainstay Capital Management's ABBV Position: Q2 2026 in Review

Mainstay Capital Management increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $3.23K and bringing the position to 1,299 shares worth $327K. The position accounts for 0.02% of the portfolio, ranked #117.

Mainstay Capital Management first reported a position in ABBV in Q4 2017 and has held it in 16 quarters since. The position peaked at $516K in Q3 2023. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Mainstay Capital Management held 1,299 shares of AbbVie worth $327K as of Q2 2026.
Mainstay Capital Management bought 15 AbbVie shares in Q2 2026, an estimated $3.23K.
AbbVie made up 0.02% of Mainstay Capital Management's portfolio in Q2 2026, its #117 holding.
Mainstay Capital Management first reported a position in AbbVie in Q4 2017 and has held it in 16 quarters since.
Mainstay Capital Management's AbbVie position peaked at $516K in Q3 2023.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mainstay Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.